The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2007
DOI: 10.1117/12.701316
|View full text |Cite
|
Sign up to set email alerts
|

Photodynamic Therapy (PDT) using intratumoral injection of the 5- aminolevulinic acid (5-ALA) for the treatment of eye cancer in cattle

Abstract: A six-year old Holstein cow with an eye cancer (ocular squamous cell carcinoma) involving the third eyelid and conjunctiva was submitted to photodynamic therapy using intratumoral 20% aminolevulinic acid (5-ALA -Aldrich Chemical Company, Milwaukee, USA) and a light emitting diode (LED -VET LED -MMOptics®) with wavelength between 600 and 700 nm, 2 cm diameter circular light beam, power of 150 mW, light dose of 50 J/cm 2 as a source of irradiation. Fifteen days after the experimental procedure we observed about … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2008
2008
2022
2022

Publication Types

Select...
3
1
1

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(9 citation statements)
references
References 4 publications
0
9
0
Order By: Relevance
“…One such second-generation photosensitiser is 5-aminolevulinic acid (ALA), a naturally occurring pro-photosensitiser and precursor for the biosynthesis of heme. For therapeutic purposes, ALA is administered topically (Morton et al, 2008(Morton et al, , 2013, orally (Muller and Wilson, 2006), or intralesionally (Hage et al, 2007;Kim et al, 2012) and enters into all cells; although uptake is potentiated by transporters of beta-amino acids and GABA (Rud et al, 2000), highly expressed on some cancer cells and neurons (Zhang et al, 2013). ALA is then metabolised to the red-fluorescent photosensitiser protoporphyrin IX (PpIX, absorption 635 nm) and finally to non-fluorescent heme (Ajioka et al, 2006, Allison andMoghissi 2013a).…”
Section: Photosensitizers For Pdtmentioning
confidence: 99%
See 3 more Smart Citations
“…One such second-generation photosensitiser is 5-aminolevulinic acid (ALA), a naturally occurring pro-photosensitiser and precursor for the biosynthesis of heme. For therapeutic purposes, ALA is administered topically (Morton et al, 2008(Morton et al, , 2013, orally (Muller and Wilson, 2006), or intralesionally (Hage et al, 2007;Kim et al, 2012) and enters into all cells; although uptake is potentiated by transporters of beta-amino acids and GABA (Rud et al, 2000), highly expressed on some cancer cells and neurons (Zhang et al, 2013). ALA is then metabolised to the red-fluorescent photosensitiser protoporphyrin IX (PpIX, absorption 635 nm) and finally to non-fluorescent heme (Ajioka et al, 2006, Allison andMoghissi 2013a).…”
Section: Photosensitizers For Pdtmentioning
confidence: 99%
“…In human patients ALA has been used for the treatment of T cell lymphoma (Coors et al, 2004), basal cell carcinoma (Kim et al, 2012) squamous cell carcinoma (SCC) and other head and neck cancers (Grant, et al, 1993, Morton et al, 1996. In veterinary medicine, ALA has been used to treat SCC in a cow (Hage et al, 2007) and in cats (Bexfield et al, 2008), sarcoids in horses (Gustafson et al, 2004, Golding et al, 2017 and transitional cell carcinoma in dogs (Lucroy et al, 2003a,b). See Tables 1 and 2. The hydrophilic nature of ALA limits its ability to deeply penetrate intact skin and thereby restricts the use of topically applied ALA-PDT to the treatment of superficial diseases, where the tissue structure is disorganised.…”
Section: Photosensitizers For Pdtmentioning
confidence: 99%
See 2 more Smart Citations
“…Many methods have been used in the handling of these wounds, from the use of local anti-septic and antibiotics up to systemic antibiotics, however, many of these wounds tend if to become chronic. In recent years researchers have investigated the effect of the photodynamic therapy in the treatment of cancers (Luckroy, 2002;Hage et al 2004 and2007;Qiang et al, 2006), dermatological diseases (Ceburkov and Gollnick, 2000;Qiang et al, 2006), to control infections caused by bacteria (Lambrechts et al 2005, Carvalho et al 2006) and fungi (Bliss et al 2004) , as well as in the treatment of cutaneous wounds (Hamblin et al 2001, Jayasree et al 2001). This technique consists of the application of a topic, intravenous or oral photosensitizer that tend to concentrate preferentially in the injured tissue and subsequent irradiation with light of a specific wave length that, in the presence of molecular oxygen unchains a photochemical reaction, inducing the release of free radicals and resulting into the death of these cells among other local effects.…”
Section: Introductionmentioning
confidence: 98%